Leerink Swann Analysts Decrease Earnings Estimates for Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) – Leerink Swann dropped their Q3 2017 EPS estimates for shares of Gilead Sciences in a report released on Monday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will post earnings of $2.01 per share for the quarter, down from their prior forecast of $2.32. Leerink Swann has a “Market Perform” rating and a $89.00 price objective on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q4 2017 earnings at $1.73 EPS, FY2017 earnings at $8.44 EPS, FY2018 earnings at $7.20 EPS, FY2019 earnings at $7.10 EPS, FY2020 earnings at $7.48 EPS and FY2021 earnings at $7.90 EPS.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same period last year, the business earned $3.08 earnings per share. The firm’s revenue was down 8.2% on a year-over-year basis. COPYRIGHT VIOLATION WARNING: “Leerink Swann Analysts Decrease Earnings Estimates for Gilead Sciences, Inc. (GILD)” was reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/10/19/leerink-swann-analysts-decrease-earnings-estimates-for-gilead-sciences-inc-gild.html.
Other equities analysts have also issued reports about the company. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a research report on Wednesday, June 21st. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research report on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. Finally, Deutsche Bank AG began coverage on Gilead Sciences in a research report on Friday, June 23rd. They issued a “buy” rating and a $79.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $85.80.
Gilead Sciences (NASDAQ:GILD) opened at 80.01 on Wednesday. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a 50 day moving average of $82.69 and a 200 day moving average of $72.48. The company has a market capitalization of $104.49 billion, a PE ratio of 8.69 and a beta of 1.14.
Institutional investors and hedge funds have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,400 shares in the last quarter. Penserra Capital Management LLC raised its holdings in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares in the last quarter. Webster Bank N. A. raised its holdings in shares of Gilead Sciences by 51.7% in the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 624 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $147,000. Finally, American Beacon Advisors Inc. purchased a new stake in shares of Gilead Sciences in the 1st quarter valued at about $143,000. 73.97% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total value of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares in the company, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 in the last three months. 1.30% of the stock is currently owned by insiders.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.60%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.